GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioXcel Therapeutics
BioXcel is a biopharmaceutical company using AI for drug development. Its stock price reflects both the success of its approved drug for the treatment of agitation and the hopes of using its platform to develop other neuroscience drugs.
Share prices of companies in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. We've categorized it under "Pharma: Neuroscience." The chart below shows how the market values companies using AI to accelerate drug discovery.
Broad Market Index - GURU.Markets
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. As a component of the GURU.Markets index, it leverages AI to accelerate drug discovery. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BTAI - Daily change in the company's share price BioXcel Therapeutics
For BioXcel Therapeutics, Inc., which uses AI for drug discovery, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in the fields of neuroscience and immuno-oncology.
Daily change in the price of a set of shares in a market segment - Pharma neurology
BioXcel Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparing it to BTAI, which uses AI for drug discovery, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. The company is located at the intersection of two hot sectors—AI and biotech. This creates high volatility, which contributes to overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioXcel Therapeutics
BioXcel Therapeutics' year-over-year performance tells the story of its AI-powered drug discovery platform. Its 12-month market cap growth reflects both sales of its approved agitation treatment and progress in clinical trials for its use in other neurological and psychiatric disorders.
Annual dynamics of market capitalization of the market segment - Pharma neurology
BioXcel Therapeutics, Inc. uses AI to develop drugs in neuroscience and immuno-oncology. Its stock price is highly volatile, reflecting both the potential of its innovative platform and the risks associated with clinical trials and commercialization of its first product.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioXcel is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioXcel Therapeutics
BioXcel Therapeutics uses AI for drug development. Its monthly performance reflects both sales of its approved drug and, to a greater extent, news from its clinical pipeline. Data on new developments, particularly in neuroscience, is a major driver of volatility.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neurology and immuno-oncology. The chart below reflects sentiment in the pharmaceutical neuroscience sector, where AI promises to accelerate the development of new drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioXcel Therapeutics uses artificial intelligence to accelerate drug development in neuroscience. Its stock price is a hybrid. On the one hand, it depends on clinical trial results, like any biotech company. On the other, it is sensitive to the general hype and investment trends in the AI sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to accelerate drug development. The company's weekly stock price is highly volatile, combining the risks of biotech with the promise of AI. News about clinical trials and FDA approvals cause sharp fluctuations, reflecting the market's assessment of its innovative approach.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to accelerate drug development. The company's weekly stock price is highly volatile, combining the risks of biotech with the promise of AI. News about clinical trials and FDA approvals cause sharp fluctuations, reflecting the market's assessment of its innovative approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioXcel, a biotech company, lives in a world of its own. Its performance is driven by news about clinical trials. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
BTAI - Market capitalization of the company BioXcel Therapeutics
The BioXcel Therapeutics market capitalization chart tells the story of how AI can be applied to drug development. Its rise after the approval of its agitation treatment and subsequent decline reflect the challenges of commercialization. It's a visualization of how the market first rewards innovation and then realistically assesses its market potential.
BTAI - Share of the company's market capitalization BioXcel Therapeutics within the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. Its share of its segment's market capitalization reflects the market's valuation of its innovative platform. The chart below shows how its weighting depends on the commercial success of its drugs and progress in clinical trials.
Market capitalization of the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neurology and immuno-oncology. The chart below shows the total market capitalization of the neuroscience pharmaceutical sector. It illustrates how modern technologies can speed up and reduce the cost of developing new drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the intersection of AI and medicine. BioXcel Therapeutics uses artificial intelligence to find new uses for existing drugs. Its market cap reflects both the successes (an approved drug for agitation) and failures of this innovative approach to drug development.
Book value capitalization of the company, segment and market as a whole
BTAI - Book value capitalization of the company BioXcel Therapeutics
BioXcel Therapeutics' foundation is its AI-powered drug discovery platform and capital for developing drugs in neuropsychiatry and oncology. This is a hybrid of IT and scientific capital. The chart shows how the company uses its capital to commercialize its approved drug and advance the rest of its portfolio.
BTAI - Share of the company's book capitalization BioXcel Therapeutics within the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. Its physical assets (laboratories) are modest compared to the power of its AI platform. The chart shows that the company's value lies in its digital and scientific infrastructure, not its physical assets.
Market segment balance sheet capitalization - Pharma neurology
AI-powered biopharmaceuticals, as the BCap_Seg chart shows, are even "easier" than traditional ones. BioXcel Therapeutics is a prime example. Its capital is invested in developing algorithms for drug discovery, reducing the need for large physical labs in the early stages.
Book value of all companies included in the broad market index - GURU.Markets
BioXcel Therapeutics' book value represents the capital and IT infrastructure for its artificial intelligence platform, which finds new applications for existing drugs. It represents the material foundation for digital R&D, which accelerates the development of tangible therapeutic solutions.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop neuroscience drugs. Its value lies in its platform and pipeline. The MvsBCap chart shows how much investors believe in its hybrid "AI+Pharma" model. Its performance will depend on both clinical trial success and news related to the application of AI in medicine.
Market to book capitalization ratio in a market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop neuroscience drugs. Its value lies in its unique drug discovery and development platform. The chart shows the premium the market is paying for its innovative approach to drug development.
Market to book capitalization ratio for the market as a whole
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. It's a combination of biotech and AI. The market is evaluating not only its drugs but also the platform for their discovery. The chart shows the high premium investors are paying for this technological approach to drug development.
Debts of the company, segment and market as a whole
BTAI - Company debts BioXcel Therapeutics
BioXcel Therapeutics, which uses AI to develop neuroscience drugs, uses debt to finance expensive and lengthy clinical trials. The journey from a digital model to an approved drug requires significant investment at each stage. This chart illustrates how the company manages its resources to bring its innovative ideas to patients.
Market segment debts - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. Combining AI and biotechnology requires investment in both IT and clinical research. This chart shows how the company funds its unique dual approach, balancing technological and pharmaceutical expenditures.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop neuroscience drugs. This chart illustrates the financial implications of its innovative business model. The high debt burden required to fund expensive R&D creates significant risks if commercialization of the developed drugs is slower than expected.
Market segment debt to market segment book capitalization - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This chart reflects debt trends in the innovative sector at the intersection of AI and pharmaceuticals. It helps understand how the company finances its unique approach to R&D compared to more traditional biotech firms.
Debt to book value of all companies in the market
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. The overall debt burden in the economy, visible in the chart, shapes the investment landscape. For innovative companies like BioXcel, access to capital to fund breakthrough research is key to their survival and growth.
P/E of the company, segment and market as a whole
P/E - BioXcel Therapeutics
For BioXcel Therapeutics, which uses AI to develop neuroscience drugs, this chart shows the market valuation of its innovative platform. The high valuations reflect investors' belief that its approach will enable faster and cheaper drug discovery, a "holy grail" for the pharmaceutical industry.
P/E of the market segment - Pharma neurology
This chart shows the average P/E for the biopharmaceutical industry, where BioXcel uses AI. The sector's high valuation reflects a belief in innovation. This metric helps understand the market premium BioXcel's technology platform commands compared to other companies developing neuroscience drugs.
P/E of the market as a whole
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. This approach should speed up and reduce the cost of drug development. This chart shows sentiment in the biotech sector. It helps understand whether the market believes in the advantages of BioXcel's AI platform and how its valuation responds to progress in clinical trials compared to traditional companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. The company combines technology and pharmaceuticals. This chart shows how analysts assess the potential of its AI-based platform to accelerate R&D and commercial success of its approved drugs.
%20P%2FE%20BioXcel%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioXcel-Therapeutics&v=1772513668349 "Chart of the company's future (projected) P/E BioXcel Therapeutics")
Future (projected) P/E of the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neuroscience and immuno-oncology. This chart shows how its future revenue expectations compare to the industry average. Does the market appreciate its innovative approach to R&D and the potential of its approved and pipeline drugs?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772513668379 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
BioXcel Therapeutics uses artificial intelligence to develop neuroscience drugs. This combination of biotech and AI makes the company sensitive to sentiment in the tech sector. This market valuation chart shows how much investors are willing to pay for innovation. Market optimism supports high valuations for such disruptive companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513668427 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. The company's profitability depends on the success of its drugs, such as its anti-anxiety drug. This chart shows the balance between commercializing already approved products and the high costs of researching new applications for its AI platform.
Profit of companies in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neurology and immuno-oncology. This approach is designed to speed up and reduce the cost of R&D. This graph shows the overall profitability of the pharmaceutical industry, where the use of AI is becoming a key competitive advantage, capable of increasing the efficiency of the entire drug development process.
Overall market profit
BioXcel Therapeutics uses artificial intelligence to develop neuroscience drugs. This is a capital-intensive business. The overall economic climate, illustrated by this chart, affects the availability of venture capital and the willingness of large pharmaceutical companies to enter into partnerships, which is critical for such innovators.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. The company's technological approach accelerates the development of new drugs. This graph reflects analysts' expectations for the effectiveness of this AI platform and the commercial success of approved and future drugs.
%20profit%20of%20the%20company%20BioXcel%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioXcel-Therapeutics&v=1772513668535 "Graph of future (projected) profit of the company BioXcel Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neurology and immuno-oncology. This approach accelerates and reduces the cost of drug development. This chart shows profitability forecasts for the biotech sector, reflecting expectations for companies using AI to revolutionize pharmaceuticals and medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772513668536 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. The company combines the risks of biotech with the potential of AI. The overall profit forecast presented here is doubly important: it influences both biotech funding and corporate willingness to invest in high-cost AI solutions.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513668553 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop neuroscience drugs. This chart shows the premium the market is paying for its innovative approach. The price-to-sales ratio reflects not so much current revenue as confidence in its technology platform and future drugs.
P/S market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This chart shows the average revenue estimate in the biotech sector. It helps understand the premium investors are willing to pay for BioXcel's innovative platform, which is designed to speed up and reduce the cost of drug development.
P/S of the market as a whole
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. Their approach aims to speed up and reduce the cost of drug development. This chart provides a general revenue metric against which to judge how highly investors value biotech companies that use AI for innovation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neurology and immuno-oncology. This chart shows how the market estimates future revenues for its drugs. This estimate depends on the commercial success of already approved products and the progress of clinical trials of other candidates discovered using its AI platform.
%20P%2FS%20BioXcel%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioXcel-Therapeutics&v=1772513668625 "The graph of the company's future (projected) P/S BioXcel Therapeutics")
Future (projected) P/S of the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neuroscience and immuno-oncology. This technological approach has the potential to accelerate the drug development process. This chart shows how investors value its AI-powered platform compared to traditional drug development methods in the biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772513668644 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This chart, reflecting the market's willingness to invest in high-tech industries, is important for BioXcel. Investor optimism allows innovative companies like BioXcel to attract the capital needed to apply cutting-edge technologies to the lengthy drug development process.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513668656 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This chart shows revenue, primarily from sales of its first approved drug for the treatment of agitation. The growth here reflects the successful introduction of the new drug into clinical practice and its acceptance by doctors and hospitals.
Sales of companies in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neuroscience and immuno-oncology. The company's business is divided into its key therapeutic programs and drugs, such as BXCL501. This chart shows the financial results of one of these innovative AI-powered pipelines.
Overall market sales
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. This approach accelerates and reduces the cost of creating new drugs. The company represents the fusion of biotechnology and AI, one of the most promising areas with the potential to transform the entire pharmaceutical industry.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neuroscience and immuno-oncology. The company's sales forecast reflects the commercial success of its first approved drug for the treatment of agitation and expectations for other candidates in its pipeline.
%20sales%20of%20the%20company%20BioXcel%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioXcel-Therapeutics&v=1772513668690 "Schedule of future (projected) sales of the company BioXcel Therapeutics")
Future (projected) sales of companies in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. This chart reflects expectations for the entire neuropharmaceutical sector. It helps understand the progress being made in treating CNS diseases and the pace of AI adoption in R&D that analysts predict, providing a backdrop for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772513668699 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
BioXcel Therapeutics uses AI to develop neuroscience drugs. The company's success depends on the investment climate in the biotech sector. This graph of overall sales forecasts reflects the state of the economy, which affects the availability of capital to finance high-tech and risky medical developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513668704 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. This chart shows the company's financial trajectory, where revenue from approved drugs is balanced against significant investments in the AI platform and the development of new candidates, resulting in the company's bottom line.
Market segment marginality - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. Their approach is aimed at increasing R&D efficiency. The graph shows whether their technological advantage translates into higher operating margins compared to traditional pharmaceutical companies.
Market marginality as a whole
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This approach allows for faster and more cost-effective drug development. This graph reflects the profitability of traditional pharmaceuticals, but for BTAI, its innovative R&D platform is key to creating future value and potential profitability.
Employees in the company, segment and market as a whole
Number of employees in the company BioXcel Therapeutics
BioXcel Therapeutics uses artificial intelligence to accelerate drug development. This chart shows a unique team combining data scientists and biologists. The size of this team reflects the investment in a hybrid model that aims to make the drug discovery process more efficient.
Share of the company's employees BioXcel Therapeutics within the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. Its innovative model requires a team that combines AI experts and biologists. This reflects its unique status as an employer at the intersection of high-tech and pharmaceuticals.
Number of employees in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. This chart shows employment in the neurological pharmaceutical sector. The growing number of specialists in this field indicates a need for new treatments for brain diseases, and BioXcel's AI-powered approach can accelerate this process.
Number of employees in the market as a whole
BioXcel Therapeutics uses AI to develop neuroscience drugs. Its growth is driven not by the overall market environment, but by the effectiveness of its technology platform. This chart provides a general overview, but for BioXcel, proving that its approach enables faster and more cost-effective drug development is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioXcel Therapeutics (BTAI)
BioXcel Therapeutics, Inc. uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This chart demonstrates its high market capitalization per employee. This is the result of the synergy between two high-value industries: biotech and AI. The market appreciates the potential of the platform created by an elite team of scientists and IT specialists.
%20of%20the%20company%20BioXcel%20Therapeutics%20(BTAI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioXcel-Therapeutics-BTAI&v=1772513668848 "Chart of market capitalization per employee (in thousands of dollars) of the company BioXcel Therapeutics (BTAI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neurology and immuno-oncology. For such an innovative company, this metric reflects the value of its technology platform and team. It demonstrates how much the market trusts their ability to effectively discover new drugs compared to traditional pharmaceutical companies.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772513668852 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
BioXcel Therapeutics uses artificial intelligence to identify and develop new drugs in neurology and immuno-oncology. Their approach promises to accelerate R&D. The chart shows the market premium for an innovative platform where technology and a small team of scientists aim to transform pharmaceuticals.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513668856 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioXcel Therapeutics (BTAI)
BioXcel Therapeutics is a biopharmaceutical company using artificial intelligence to discover and develop drugs in neuroscience. Their key drug (IGALMI) is approved for the treatment of agitation. This chart shows how effectively the company has transitioned from R&D to commercialization. It measures how successfully their sales and marketing team can monetize an approved drug, generating revenue per employee.
%20Chart%20BioXcel%20Therapeutics%20(BTAI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioXcel-Therapeutics-BTAI&v=1772513668858 "Company Profit Per Employee (in thousands of dollars) Chart BioXcel Therapeutics (BTAI)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. Their business model leverages technology to achieve high R&D productivity. This chart shows how much more effective their AI-powered team is at creating value compared to the average of traditional pharmaceutical companies.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772513668860 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
BioXcel uses AI for neuroscience drug development and already has an approved drug (IGALMI). This metric is critical here. It shows how well commercial sales revenue (generated by the marketing team) covers the costs of the expensive R&D team and AI platform needed to develop new drugs. It's a balance between science and commerce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513668864 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioXcel Therapeutics (BTAI)
BioXcel Therapeutics uses artificial intelligence to develop drugs in neuroscience and immuno-oncology. This chart reflects the successful commercialization of its first drug. The increase in revenue per employee demonstrates how an innovative approach to development can lead to the creation of a highly sought-after product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioXcel-Therapeutics-BTAI&v=1772513668869 "Sales chart per company employee BioXcel Therapeutics (BTAI)")
Sales per employee in the market segment - Pharma neurology
BioXcel Therapeutics uses AI to identify new uses for existing drugs, focusing on neuroscience and immuno-oncology. It's an IT biopharma. This chart compares BTAI's revenue per employee to the industry average. It demonstrates how productive their AI platform is in discovering and commercializing new therapeutic solutions.
Sales per employee for the market as a whole
BioXcel Therapeutics uses AI to develop neuroscience drugs. Their first drug (Igalmi) is approved for the treatment of agitation. This chart shows how effectively their commercial team is marketing this drug, and how much revenue their R&D platform generates per employee (scientist, AI specialist).
Short shares by company, segment and market as a whole
Shares shorted by company BioXcel Therapeutics (BTAI)
BioXcel Therapeutics (BTAI) uses AI to find new uses for old drugs. Their key drug is approved for the treatment of agitation. However, the company has encountered challenges in other areas of research. This chart shows the number of investors who believe the company's potential is limited to a single drug and its AI platform is ineffective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioXcel-Therapeutics-BTAI&v=1772513668891 "Short Shares Chart for the Company BioXcel Therapeutics (BTAI)")
Shares shorted by market segment - Pharma neurology
BioXcel Therapeutics uses AI to find new uses for existing drugs. Their main success is a drug for the treatment of agitation in schizophrenia and bipolar disorder. This chart shows the odds against the CNS-focused biotech sector. It reflects market skepticism regarding the drug's commercial potential or the success of the AI platform.
Shares shorted by the overall market
BioXcel (BTAI) is a biotech company using AI to develop drugs. It's a speculative "hype" stock. When this general fear indicator rises, investors flee the hype. They fear that unprofitable AI biotechs like BTAI won't survive a recession, so they sell them off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioXcel Therapeutics (BTAI)
BioXcel Therapeutics uses AI for neuroscience drug development. The company received approval for one drug but encountered challenges. This chart shows how the market reacts to these swings: "overbought" (above 70) on approval news and "oversold" (below 30) on commercialization issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioXcel-Therapeutics-BTAI&v=1772513668897 "RSI 14 indicator chart for the company's stock BioXcel Therapeutics (BTAI)")
RSI 14 Market Segment - Pharma neurology
BioXcel Therapeutics uses AI to identify new uses for existing drugs. Their main product is a drug for the treatment of agitation in schizophrenia/bipolar disorder. This chart measures the collective excitement in the neuroscience biotech sector. It helps separate BTAI volatility from the overall industry trend.
RSI 14 for the overall market
For BioXcel Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BTAI (BioXcel Therapeutics)
BioXcel Therapeutics uses AI to develop neuroscience drugs. Its flagship drug, Igalmi, treats agitation. This chart shows the average target price. Analysts' forecasts depend on the pace of Igalmi's commercial launch and the value of their AI platform for future development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BTAI-BioXcel-Therapeutics&v=1772513668919 "A chart showing analyst consensus forecasts for the expected stock price. BTAI (BioXcel Therapeutics)")
The difference between the consensus estimate and the actual stock price BTAI (BioXcel Therapeutics)
BioXcel Therapeutics uses AI to develop neuroscience drugs. Their flagship drug (IGALMI) is a rapid-release anti-agitation treatment. This chart shows how far the current stock price differs from the "fair" price predicted by analysts. It reflects their confidence in the commercial success of IGALMI and their AI R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BTAI-BioXcel-Therapeutics&v=1772513668921 "A chart showing the difference between the consensus forecast and the actual stock price. BTAI (BioXcel Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
BioXcel Therapeutics is a biotech company using AI for drug development. Its first success is Igalmi, a drug for the rapid relief of agitation. This chart shows analysts' overall expectations for the neuroscience sector, reflecting whether experts believe this AI platform will be commercially successful.
Analysts' consensus forecast for the overall market share price
BioXcel Therapeutics uses AI to develop neuroscience drugs, and their key product (Igalmi) is approved for the treatment of agitation. This chart shows overall market sentiment. For BTAI, as a commercialization-stage company in a risky sector, overall optimism is important, as it supports a high valuation and the funding needed to bring the product to market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioXcel Therapeutics
BioXcel uses AI to accelerate R&D. Their first success is a drug for the treatment of neurological agitation (Igalmi). This chart is a summary indicator of their AI model. It weighs their commercial launch (sales of Igalmi) against the market's confidence in their R&D platform and its ability to quickly find new AI-approved targets, optimizing development costs.
AKIMA Market Segment Index - Pharma neurology
BioXcel Therapeutics (BTAI) is using artificial intelligence to revolutionize drug development, particularly in neurology. Their approved drug, IGALMI, treats agitation, demonstrating their data-driven approach. This chart shows the average index value for the neurology pharmaceutical segment. It provides a benchmark for assessing whether BTAI's AI model delivers superior value compared to the average.
The AKIM Index for the overall market
BioXcel Therapeutics is a biopharmaceutical company using AI to discover new indications for existing drugs (neurology, oncology). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this technologically advanced drug repurposing platform.
